NCT01029873 - QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

September 30, 2013

Conditions

Metastatic Melanoma

Interventions

DRUG

Cisplatin

Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course

BIOLOGICAL

ALT-801

"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"

Trial Locations (8)

18015

St. Luke's Hospital and Health Network, Bethlehem

28204

Carolinas Medical Center-Brumenthal Cancer Center, Charlotte

30322

Emory University, Atlanta

32806

MD Anderson Cancer Center Orlando, Orlando

52242

University of Iowa Hospitals and Clinics, Iowa City

60611

Northwestern University, Chicago

90025

The Angeles Clinic and Research Institute, Los Angeles

98109

University of Washington, Seattle Cancer Care Center, Seattle